Janus Henderson Group’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-67,379
| Closed | -$4.65M | – | 2446 |
|
|
2025
Q2 | $4.65M | Sell |
67,379
-316,551
| -82% | -$21.5M | ﹤0.01% | 925 |
|
|
2025
Q1 | $26.6M | Sell |
383,930
-112,158
| -23% | -$9.26M | 0.01% | 504 |
|
|
2024
Q4 | $42.7M | Sell |
496,088
-396,339
| -44% | -$42.9M | 0.02% | 410 |
|
|
2024
Q3 | $106M | Sell |
892,427
-1,170
| -0.1% | -$156K | 0.05% | 272 |
|
|
2024
Q2 | $128M | Sell |
893,597
-424,113
| -32% | -$56.2M | 0.07% | 234 |
|
|
2024
Q1 | $169M | Sell |
1,317,710
-251,854
| -16% | -$30M | 0.09% | 199 |
|
|
2023
Q4 | $162M | Buy |
1,569,564
+263,279
| +20% | +$26M | 0.1% | 200 |
|
|
2023
Q3 | $119M | Buy |
1,306,285
+325,063
| +33% | +$28.6M | 0.08% | 224 |
|
|
2023
Q2 | $79.4M | Buy |
981,222
+658,830
| +204% | +$53.8M | 0.05% | 292 |
|
|
2023
Q1 | $25.7M | Sell |
322,392
-38,878
| -11% | -$2.76M | 0.02% | 518 |
|
|
2022
Q4 | $24.4M | Sell |
361,270
-371,802
| -51% | -$21.8M | 0.02% | 522 |
|
|
2022
Q3 | $36.5M | Buy |
733,072
+364,108
| +99% | +$19.5M | 0.01% | 565 |
|
|
2022
Q2 | $20.6M | Sell |
368,964
-23,138
| -6% | -$1.28M | 0.01% | 561 |
|
|
2022
Q1 | $21.8M | Sell |
392,102
-22,296
| -5% | -$1.14M | 0.01% | 729 |
|
|
2021
Q4 | $23.2M | Sell |
414,398
-21,894
| -5% | -$1.19M | 0.01% | 750 |
|
|
2021
Q3 | $20.9M | Buy |
436,292
+9,256
| +2% | +$447K | 0.01% | 783 |
|
|
2021
Q2 | $17.9M | Sell |
427,036
-4,698
| -1% | -$182K | 0.01% | 814 |
|
|
2021
Q1 | $14.6M | Buy |
431,734
+41,396
| +11% | +$1.47M | 0.01% | 837 |
|
|
2020
Q4 | $13.6M | Sell |
390,338
-88,770
| -19% | -$3.07M | 0.01% | 820 |
|
|
2020
Q3 | $16.6M | Buy |
479,108
+48,422
| +11% | +$1.61M | 0.01% | 748 |
|
|
2020
Q2 | $14.1M | Buy |
430,686
+8,186
| +2% | +$261K | 0.01% | 764 |
|
|
2020
Q1 | $12.7M | Sell |
422,500
-13,042
| -3% | -$388K | 0.01% | 774 |
|
|
2019
Q4 | $12.6M | Sell |
435,542
-48,396
| -10% | -$1.34M | 0.01% | 919 |
|
|
2019
Q3 | $12.5M | Sell |
483,938
-14,882
| -3% | -$376K | 0.01% | 906 |
|
|
2019
Q2 | $12.7M | Buy |
498,820
+3,198
| +0.6% | +$79K | 0.01% | 897 |
|
|
2019
Q1 | $13M | Buy |
495,622
+50,764
| +11% | +$1.25M | 0.01% | 865 |
|
|
2018
Q4 | $10.2M | Buy |
444,858
+27,352
| +7% | +$608K | 0.01% | 891 |
|
|
2018
Q3 | $9.84M | Buy |
417,506
+9,682
| +2% | +$236K | 0.01% | 936 |
|
|
2018
Q2 | $9.4M | Sell |
407,824
-12,192
| -3% | -$290K | 0.01% | 933 |
|
|
2018
Q1 | $10.3M | Sell |
420,016
-13,704
| -3% | -$360K | 0.01% | 896 |
|
|
2017
Q4 | $11.6M | Buy |
433,720
+15,252
| +4% | +$388K | 0.01% | 847 |
|
|
2017
Q3 | $10.1M | Sell |
418,468
-9,112
| -2% | -$206K | 0.01% | 865 |
|
|
2017
Q2 | $9.17M | Buy |
+427,580
| New | +$8.63M | 0.01% | 887 |
|
Other funds holding NVO
F
Janus Henderson Group's NVO Position: Q3 2025 in Review
Janus Henderson Group sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 67,379 shares — an estimated $4.65M sold.
Janus Henderson Group first reported a position in NVO in Q2 2017 and held it in 33 quarters. The position peaked at $169M in Q1 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.
- Janus Henderson Group reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
- Janus Henderson Group sold 67,379 Novo Nordisk shares in Q3 2025, an estimated $4.65M.
- Janus Henderson Group first reported a position in Novo Nordisk in Q2 2017 and held it in 33 quarters.
- Janus Henderson Group's Novo Nordisk position peaked at $169M in Q1 2024.
- 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.
Based on Janus Henderson Group's 13F filing for Q3 2025, filed 14 Nov 2025.